Company intelligence / Profile preview

Pairnomix

Minneapolis, Minnesota, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Pairnomix developed personalized genetic evaluation services and in vitro CNS disease models (including seizure-in-a-dish models) to identify repurposed approved drugs and novel modalities (such as antisense oligonucleotides) for individuals with rare genetic epilepsies and other CNS disorders; it did not advance its own therapeutics into clinical trials before combining with Q-State Biosciences.[1][2][5][8]

Therapeutic areas: Neurology
Modalities: Small moleculeAntisense oligonucleotide
Industry: Molecular Diagnostics

Partnerships

StemoniX

Beyond the preview

Go deeper on Pairnomix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pairnomix.

Explore the full profile